Another in vivo study determined that activating ERβ by its agonist DPN resulted in anticancer activities such as inhibition of angiogenesis, lymphangiogenesis, tumor growth, Ki67, BAFF, and GRB7 expression [136]. This evidence concerns the gene ESR2 and neoplasm.